NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 14, 2018

Study Completion Date

August 9, 2018

Conditions
Cardiac ArrestHypothermiaCritical Care
Interventions
BIOLOGICAL

"NSE dosage hypothermia arm"

There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.

BIOLOGICAL

"NSE dosage normothermia arm"

There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.

Trial Locations (14)

Unknown

Medical Surgical Intensive Care Unit, Annecy

Medical Intensive Care Unit, Clermont-Ferrand

Medical Intensive Care Unit, Dijon

Medical Surgical Intensive Care Unit, La Roche-sur-Yon

Medical Surgical Intensive Care Unit, Lens

Medical Surgical Intensive Care Unit, Limoges

Medical Surgical Intensive Care Unit, Montauban

Medical Intensive Care Unit, Nantes

Medical Surgical Intensive Care Unit, Orléans

Medical Intensive Care Unit, Poitiers

Medical Surgical Intensive Care Unit, Rodez

Medical Surgical Intensive Care Unit, Saint-Brieuc

Medical Surgical Intensive Care Unit, St-Malo

Medical Intensive Care Unit, Tours

All Listed Sponsors
lead

Centre Hospitalier Departemental Vendee

OTHER

NCT02722473 - NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial. | Biotech Hunter | Biotech Hunter